arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Cytek Biosciences, Inc.

CTKB

$5.72 ▲ +0.43 (+8.13%) at close

7 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Cytek Biosciences, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $730.7M

Dividend Yield —

Revenue Growth 0.5% ↘

Op. Margin -20.0% ↘

ROIC -26.3% ↘

FCF / Share $-0.07 ↘

Trailing P/E —

Price / Book 2.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 22, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$201.49M

↑ +0.5% —

Net Income Profit after all expenses

$-66.54M

↓ -1005.3% —

Operating Margin Operating profit as % of sales

-20.0%

↓ -95.8% 10th

FCF / Share Free cash flow per share

$-0.07

↓ -141.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability

Returns

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	0.5% Caution ↓ Caution Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-90%)	3.9% Caution ↓ Caution Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-23%)	17.7% Good ↓ Good Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+253%)	28.2% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+464%)	37.8% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+656%)	—	—
Net Income Growth YoY (%)	-1005.3% Weak ↓ Weak Declining Year-over-year change in net income	50.4% Excellent ↑ Excellent Improving Year-over-year change in net income	N/M	-17.9% Weak Weak Year-over-year change in net income	-84.4% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	N/M	3475.9% Excellent Excellent Year-over-year change in free cash flow	N/M	N/M	-99.3% Weak Weak Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	7.1% Fair ↓ Fair Declining Compound annual revenue growth over 3 years	16.1% Excellent Excellent Compound annual revenue growth over 3 years	27.6% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	16.8% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Operating Margin (%) (%)	-20.0% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-267%)	-10.2% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-185%)	-14.4% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-220%)	-1.1% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-109%)	7.2% Caution Caution Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-40%)	14.7% Fair Fair Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+23%)	—
Effective Tax Rate (%) (%)	-123.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-5.6% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	22.7% Fair ↑ Fair Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-97.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	49.0% Weak Weak Actual taxes paid relative to pre-tax income Optimal: 15-25%	-34.5% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	-33.0% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-513%)	-3.0% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-138%)	-6.3% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-179%)	1.5% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-81%)	2.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-70%)	20.9% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+161%)	—
FCF Margin (%) (%)	-4.4% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	10.9% Fair ↑ Fair Improving Free cash flow as a percentage of revenue Optimal: > 10%	0.3% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-13.4% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	0.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	14.7% Fair Fair Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.13x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-3.63x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	-0.05x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-8.85x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.09x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.70x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-26.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-5.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-5.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-0.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	1.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-114.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-8.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-4.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-5.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-0.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	2.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	6.2% Caution Caution Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-19.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-230%)	-1.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-110%)	-3.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-121%)	0.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-96%)	0.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-95%)	-121.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-907%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Interest Coverage (x)	—	—	-13.45x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-0.70x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	5.26x Good Good Operating income divided by interest expense Optimal: > 5x	41.02x Excellent Excellent Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-90.85M	$-98.72M	$-167.30M	$-296.60M	$-364.62M	$-165.23M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$1.58	$1.53	$1.43	$1.22	$1.67	$3.19	—
Basic EPS, GAAP (USD)	—	—	$-0.09	$0.02	$0.00	$0.11	—
Free Cash Flow per Share (USD)	$-0.07	$0.17	$0.00	$-0.16	$0.00	$0.47	—
Book Value per Share (USD)	$2.66	$3.06	$3.01	$3.14	$3.03	$-0.51	—
Tangible Book Value per Share (USD)	$2.40	$2.78	$2.71	$3.04	$2.92	$-0.54	—
Basic Weighted Avg Shares (shares)	127.75M	130.61M	135.28M	134.51M	76.74M	29.13M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$314.19M	$328.78M	$335.83M	$404.98M	$398.55M	$182.09M	—
Total Equity (USD)	$341.74M	$395.74M	$393.06M	$425.55M	$405.38M	$-16.03M	$41.70M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$201.49M	$200.45M	$193.01M	$164.04M	$127.95M	$92.84M	—
Depreciation Expense (USD)	$7.58M	$7.21M	$6.05M	$2.49M	$1.24M	$603.00K	—
Net Income, GAAP (USD)	$-66.54M	$-6.02M	$-12.15M	$2.48M	$3.03M	$19.41M	—
Operating Cash Flow (USD)	$-4.69M	$25.38M	$5.28M	$-12.23M	$4.63M	$15.16M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters

Cytek Biosciences, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CTKB with peers